

Date: 12/02/2021

Subject: phone call with EFPIA

Participants: DG SANTE: Sandra Gallina (SG), Pierre Delsaux (PD), [REDACTED]
[REDACTED] – EFPIA: [REDACTED] (NM)

- **Export licensing**
SG presented the origin, rationale and functioning of the export-licensing scheme, aimed to ensure transparency of flows of vaccines.
NM presented EFPIA's perspective. EFPIA supports transparency, but is concerned by potential delays caused by the export authorisation process. An EFPIA WG will discuss possibilities to speed up the export authorisation process.
- **Structured approach to manufacturing / IP**
EFPIA will announce initiatives on IP, to avoid compulsory licensing. In IT, companies will announce that they are available to produce vaccines. Other MS may follow.
EFPIA would welcome a structured approach to vaccine production capacity. Commissioner Breton is looking into possibilities of increasing production capacity.
PD informed about an upcoming Communication on bio preparedness, with emphasis on variants and agile production capacity.
- **Pharma strategy**
EFPIA to identify date with PD for 'pipeline review' event. EFPIA calls for a forum to discuss concrete proposals under the strategy.
SG indicated the importance for pharma to assume its societal responsibility, help address the problems of access to medicines in the smaller markets (notably post BREXIT) and actively contribute to the pharmaceutical strategy. Important to 'fix' the system together.
EFPIA is working on measures to improve transparency and access to medicines.
- **HERA**
EFPIA is preparing feedback on the inception impact assessment to share with the Commission next week.